Diabetes Mellitus Type 2 in ObeseCarborCalNCT05801614
Normalized Glucose Levels in Type 2 Diabetes With Carbohydrate or Caloric Restriction
A study testing Low carb diet in people with Diabetes Mellitus Type 2 in Obese, run by Region Stockholm at 1 site in Sweden.
Trial summary
This is a randomized controlled trial to determine whether a low-carbohydrate (LC) diet can lead to normalized blood glucose levels in patients with short duration of type 2 diabetes (T2D). Read more about this study
- Who is it for?
- Ages 24 to 70 years
- Conditions the study is for
- Diabetes Mellitus Type 2 in Obese
- What is being tested?
- Low carb diet
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 286 participants
- Where
- 1 siteSweden
- Study dates
- 28 Feb 2022to 28 Feb 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 24 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- HbA1c > 48 mmol/mol (with or without medical treatment);
- less than 6 years since the diagnosis of T2D
- BMI ≥ 27 kg/m2 (≥ 25 kg/m2 for Asians).
Who cannot join
- Insulin deficiency.
- HbA1c concentration of 12% or more (≥108 mmol/mol),
- treatment with sulphonyl urea or sodium-glucose-cotrasporter2-inhibitor (SGL2-i),
- myocardial infarction within the previous 6 months,
- severe or unstable heart failure
- other severe diseases including cancer, psychiatric/eating disorders, severe depression - substance abuse,
- conditions that may affect the ability of patients to participate in the study
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Sweden1 site, 1 recruiting
- Recruiting
Center for diabetes, Academic Specialist center
Stockholm
Katarina Fagerskiold, nurse, +46-8-123 671 76., katarina.fagerskiold@regionstockholm.se
Neda Rajamand Ekberg, M.D; PhD
About this study
Official title: Normalized Glucose Levels in Type 2 Diabetes With Carbohydrate or Caloric Restriction: a Randomized Controlled Trial (CarborCal)
This is a randomized controlled trial to determine whether a low-carbohydrate (LC) diet can lead to normalized blood glucose levels in patients with short duration of type 2 diabetes (T2D). Previous studies have shown that caloric restricted diet leading to weight loss can normalize blood glucose levels in approximately 50% of patients with a short duration of diabetes type 2. However, caloric restriction is difficult to maintain. Less restrictive approaches are needed. The hypothesis in this study is that Low carbohydrate diet can results in normalized blood glucose levels in T2D and can be an alternative to caloric restriction diet, both in the shorter term (3 months) and longer term (15 months). The outcome of this study leading to reduction of HbA1c is important for prevention of diabetes complications.
Read the detailed description
Background Overweight and obesity raise the risk of hyperglycemia which is among the strongest risk factors for morbidity and mortality globally, linked to type 2 diabetes (T2D) as well as, e.g., cardiovascular diseases (CVD), several cancers, dementia, complicated pregnancies and non-alcoholic fatty liver disease.1 The link between obesity, T2D and CVD is partially explained by the visceral adiposity and ectopic (e.g., hepatic) fat associated with insulin resistance, glucose intolerance, arterial stiffness, high blood pressure and dyslipidaemia constituting the metabolic syndrome.2,3 Recent studies have demonstrated that diet-induced weight loss, averaging just over 10 kg at 12-months, can effectively normalize blood glucose levels in T2D in a large proportion of patients. While energy-restrictive diets can enable rapid weight loss, any restrictive diet can be difficult to maintain over time. Strict weight loss diet is difficult to follow. Less restrictive approaches that can be adopted as part of a healthy lifestyle would be ideal.
Cardiovascular complications are the leading cause of morbidity and mortality among patients with diabetes. 29 The mechanisms of diabetes mellitus-associated progression of atherosclerosis are not fully understood. Hyperglycemia has been shown to cause increased oxidative stress arising from oxi-dative degradation of glucose metabolites. Similarly, advanced glycosylation endproducts (AGEs), which are the result of intracellular hyperglycemia, have been shown to be involved in mediating vascular damage. Furthermore hyperglycemia has been reported that to lead to a hypercoagulable state.29 Low carbohydrate diet has recently gained popularity. Rresearch questions remain on if LC diet with low GI can lead to normalization of blood glucose levels and decrease cardiovascular risk markers. The ideal energy percentage (E%) of carbohydrate in the diet for optimal glucose levels is unclear. Caloric restriction diet has shown best results for normalisation of blood glucose levels. There are no previous studies comparing LC diet with caloric restricted diet in regard to normalization of blood glucose levels. The main goal of this study is to evaluate if LC with low GI can lead to normalization or improvement of blood glucose levels in type 2 diabetes (T2D) and to explore the mechanism for normalization of blood glucose levels after LC diet and caloric restricted diet.
The main hypothesis in this study is that Low carbohydrate diet can results in normalization or improvement of blood glucose levels in patients with T2D with short duration of disease both in the shorter term (3 months) and longer term (15 months).
286 patients with type 2 diabetes will be included in this study. Patients will be randomized to a low Carb diet or a low caloric diet for 15 months.
Previous study on caloric restriction diet (DIRECT trial) showed normalization of blood glucose levels in 46% of participants after 12 months. Previous studies on LC diet have shown different results on blood glucose levels based on differences in study design. The greater the carbohydrate restriction, the greater glucose lowering effect. There is a lack of studies reporting normalisation of blood glucose levels. Therefore, it was assumed that LC dietary strategies can result in normalization of blood glucose levels in 30% of patients with T2D after 3 and 15 months. Using an online sample size calculator for a study power of 80% and alpha value of 0.05 the sample size was calculated to 143 participants in each group.
Anthropometric data and blood samples will be collected at baseline and after 3 months (initial weight loss and remission) months (continued weight loss and remission), and 15 months (weight maintenance). For security reason Hb1c and lipid status will be analyzed after changes in medication. For Standardized measurement protocols, instruments (e.g., for anthropometrics), collection tubes, etc. will be used. HbA1c, glucose, lipids and other standard biochemical variables will be measured directly on the day of the visit at the laboratories, or, for substances sensitive to batch effects (e.g., serum insulin), after collection and freezing at -80°C. Samples that are not analyzed immediately will be stored in a biobank for later use. The study will be performed in accordance with GCP.
Controlled diet that leads to weight reduction can reverse type 2 diabetes or delay the diagnosis of T2D. According to the report from the Swedish Institute for Health and Healthcare Economi (IHE) decreasing the blood sugar levels in patient with T2D will spare 800 cases of heart infarction, 500 cases of stroke, 450 cases of kidney failure and 20 cases of blindness. Delaying the diabetes diagnosis is beneficial for the patients since the diabetes complications are directly correlated to the diabetes duration. Patient with type 2 diabetes who change their diet with less carbohydrate have shown to need less insulin. The cost of diabetes disease is affected by the cost of medications and the cost of complications of diabetes. Improved knowledge about which diet can reverse T2D and improve glucose levels will in the end affect the cost for the type 2 diabetes. Dietary intervention which effectively improve blood sugar levels will have significant positive health economic effects. The result from this study will be used for diet recommendation for patients with T2D.
Both men and women will be included in the study. Sex will also be one of the factors in randomisation to assure both groups have equal percent of men and women. Gender is considered a risk factor for obesity. Previous studies have shown that being female doubles the chance of becoming overweight. It is known that lifestyle intervention programs are effective in the prevention of type 2 diabetes mellitus in high-risk populations. However, most studies report poorly about the influence of sex and/or gender effectiveness of these interventions. Male sex is acknowledged as a diabetes risk factor. Men are marginally higher affected by diabetes all over the world. They are diagnosed at younger age and at lower levels of overweight/obesity. Women on the other hand are the majority of participants in weight loss studies (This was also observed this in our study investigating the effect of intermittent fasting). Women show greater weight control involvement and thus seek medical help for weight loss therapy/surgery earlier. It is not known if men and women have different preference for LC-diet or caloric restriction as strategies for weigh maintenance. We will be able to compare the remission rate for T2D in men and women.
- Conditions
- Diabetes Mellitus Type 2 in Obese
- Being tested
- Low carb diet
- Keywords
- Diabetes Mellitus Type 2, Diet, Carbohydrate-Restricted, Caloric restriction
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Low carb dietOther
Also called Low calori diet
Low calori diet
| Study group | Role | What they receive |
|---|---|---|
| Low Carb diet | Other | Participants will have acces to a plattform with recepies containing 30 g carbohydrate / day during the first three months and thereafter recepies containing 80 g carbohydrate/ day during the remaining 12 months Receives: Other: Low carb diet |
| Low Calori diet | Other | Participants will be asked to by low caloric diet replacement containing 850 kCal/day during the first 3 months, aiming for a weight loss of 10 kg during and thereafter will have access to recepies containing less calorie for weight maintenance during the remaining 12 months Receives: Other: Low carb diet |
What is being measured
The primary outcome is the main question the study is designed to answer.
non-diabetic HbA1c
HbA1c below 48 mmol/mol without antidiabetic medication
Measured: After 3 months
non diabetic HbA1c
HbA1c below 48 mmol/mol without antidiabetic medication
Measured: After 15 months
Secondary outcomes (5)
Changes in HbA1c
Changes in HbA1c from base line to 3 and 15 months
Measured: After 3 and 15 months
Percent of participants with HbA1c below 48 and 42 mmol/mol
Number of participants with HbA1c below 48 and 42 both on and without antidiabetic medication
Measured: After 3 and 15 months
Changes in Fasting glucose levels
Changes in fasting plasma glucose levels after 3 and 15 months
Measured: After 3 and 15 months
Changes in HOMA-IR
Changes in HOMA_IR afte 3 and 15 months
Measured: After 3 and 15 months
Changes in Insulin secretion
Changes in Insulin secretion measured by glucagon stimulation test
Measured: After 3 and 15 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Apr 2023
- Study start28 Feb 2022
- Primary completion28 Feb 2027 (estimated)
- Study completion28 Feb 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Diabetes Mellitus Type 2 in ObeseStudies of the same condition, open and under way.
- More trials run by Region StockholmThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 286 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Region Stockholm
- Sponsor type
- Other government
- Responsible party
- Principal investigator, Neda Ekberg, Region Stockholm
- Investigators
- Neda Rajamand Ekberg, MD, PhD, Principal investigator, Region Stockholm
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05801614
- Sponsor's protocol ID
- Dnr 2020-06848
- Acronym
- CarborCal
- Status last verified
- Dec 2023
- First submitted
- 2 Jan 2023
- Last updated
- 2 Jan 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jan 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Normalized Glucose Levels in Type 2 Diabetes With Carbohydrate or Caloric Restriction: a Randomized Controlled Trial (CarborCal)
- ClinicalTrials.gov ID
- NCT05801614
- Acronym / sponsor ID
- CarborCal / Dnr 2020-06848
- Conditions
- Diabetes Mellitus Type 2 in Obese
- Keywords
- Diabetes Mellitus Type 2, Diet, Carbohydrate-Restricted, Caloric restriction
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 286 participants (estimated)
- Lead sponsor
- Region StockholmOther government
- Study start
- 28 Feb 2022 (actual)
- Primary completion
- 28 Feb 2027 (estimated)
- Study completion
- 28 Feb 2027 (estimated)
- First posted
- 6 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a randomized controlled trial to determine whether a low-carbohydrate (LC) diet can lead to normalized blood glucose levels in patients with short duration of type 2 diabetes (T2D). Previous studies have shown that caloric restricted diet leading to weight loss can normalize blood glucose levels in approximately 50% of patients with a short duration of diabetes type 2. However, caloric restriction is difficult to maintain. Less restrictive approaches are needed. The hypothesis in this study is that Low carbohydrate diet can results in normalized blood glucose levels in T2D and can be an alternative to caloric restriction diet, both in the shorter term (3 months) and longer term (15 months). The outcome of this study leading to reduction of HbA1c is important for prevention of diabetes complications.
Detailed description
Background Overweight and obesity raise the risk of hyperglycemia which is among the strongest risk factors for morbidity and mortality globally, linked to type 2 diabetes (T2D) as well as, e.g., cardiovascular diseases (CVD), several cancers, dementia, complicated pregnancies and non-alcoholic fatty liver disease.1 The link between obesity, T2D and CVD is partially explained by the visceral adiposity and ectopic (e.g., hepatic) fat associated with insulin resistance, glucose intolerance, arterial stiffness, high blood pressure and dyslipidaemia constituting the metabolic syndrome.2,3 Recent studies have demonstrated that diet-induced weight loss, averaging just over 10 kg at 12-months, can effectively normalize blood glucose levels in T2D in a large proportion of patients. While energy-restrictive diets can enable rapid weight loss, any restrictive diet can be difficult to maintain over time. Strict weight loss diet is difficult to follow. Less restrictive approaches that can be adopted as part of a healthy lifestyle would be ideal.
Cardiovascular complications are the leading cause of morbidity and mortality among patients with diabetes. 29 The mechanisms of diabetes mellitus-associated progression of atherosclerosis are not fully understood. Hyperglycemia has been shown to cause increased oxidative stress arising from oxi-dative degradation of glucose metabolites. Similarly, advanced glycosylation endproducts (AGEs), which are the result of intracellular hyperglycemia, have been shown to be involved in mediating vascular damage. Furthermore hyperglycemia has been reported that to lead to a hypercoagulable state.29 Low carbohydrate diet has recently gained popularity. Rresearch questions remain on if LC diet with low GI can lead to normalization of blood glucose levels and decrease cardiovascular risk markers. The ideal energy percentage (E%) of carbohydrate in the diet for optimal glucose levels is unclear. Caloric restriction diet has shown best results for normalisation of blood glucose levels. There are no previous studies comparing LC diet with caloric restricted diet in regard to normalization of blood glucose levels. The main goal of this study is to evaluate if LC with low GI can lead to normalization or improvement of blood glucose levels in type 2 diabetes (T2D) and to explore the mechanism for normalization of blood glucose levels after LC diet and caloric restricted diet.
The main hypothesis in this study is that Low carbohydrate diet can results in normalization or improvement of blood glucose levels in patients with T2D with short duration of disease both in the shorter term (3 months) and longer term (15 months).
286 patients with type 2 diabetes will be included in this study. Patients will be randomized to a low Carb diet or a low caloric diet for 15 months.
Previous study on caloric restriction diet (DIRECT trial) showed normalization of blood glucose levels in 46% of participants after 12 months. Previous studies on LC diet have shown different results on blood glucose levels based on differences in study design. The greater the carbohydrate restriction, the greater glucose lowering effect. There is a lack of studies reporting normalisation of blood glucose levels. Therefore, it was assumed that LC dietary strategies can result in normalization of blood glucose levels in 30% of patients with T2D after 3 and 15 months. Using an online sample size calculator for a study power of 80% and alpha value of 0.05 the sample size was calculated to 143 participants in each group.
Anthropometric data and blood samples will be collected at baseline and after 3 months (initial weight loss and remission) months (continued weight loss and remission), and 15 months (weight maintenance). For security reason Hb1c and lipid status will be analyzed after changes in medication. For Standardized measurement protocols, instruments (e.g., for anthropometrics), collection tubes, etc. will be used. HbA1c, glucose, lipids and other standard biochemical variables will be measured directly on the day of the visit at the laboratories, or, for substances sensitive to batch effects (e.g., serum insulin), after collection and freezing at -80°C. Samples that are not analyzed immediately will be stored in a biobank for later use. The study will be performed in accordance with GCP.
Controlled diet that leads to weight reduction can reverse type 2 diabetes or delay the diagnosis of T2D. According to the report from the Swedish Institute for Health and Healthcare Economi (IHE) decreasing the blood sugar levels in patient with T2D will spare 800 cases of heart infarction, 500 cases of stroke, 450 cases of kidney failure and 20 cases of blindness. Delaying the diabetes diagnosis is beneficial for the patients since the diabetes complications are directly correlated to the diabetes duration. Patient with type 2 diabetes who change their diet with less carbohydrate have shown to need less insulin. The cost of diabetes disease is affected by the cost of medications and the cost of complications of diabetes. Improved knowledge about which diet can reverse T2D and improve glucose levels will in the end affect the cost for the type 2 diabetes. Dietary intervention which effectively improve blood sugar levels will have significant positive health economic effects. The result from this study will be used for diet recommendation for patients with T2D.
Both men and women will be included in the study. Sex will also be one of the factors in randomisation to assure both groups have equal percent of men and women. Gender is considered a risk factor for obesity. Previous studies have shown that being female doubles the chance of becoming overweight. It is known that lifestyle intervention programs are effective in the prevention of type 2 diabetes mellitus in high-risk populations. However, most studies report poorly about the influence of sex and/or gender effectiveness of these interventions. Male sex is acknowledged as a diabetes risk factor. Men are marginally higher affected by diabetes all over the world. They are diagnosed at younger age and at lower levels of overweight/obesity. Women on the other hand are the majority of participants in weight loss studies (This was also observed this in our study investigating the effect of intermittent fasting). Women show greater weight control involvement and thus seek medical help for weight loss therapy/surgery earlier. It is not known if men and women have different preference for LC-diet or caloric restriction as strategies for weigh maintenance. We will be able to compare the remission rate for T2D in men and women.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Low Carb diet | Other | Other: Low carb dietParticipants will have acces to a plattform with recepies containing 30 g carbohydrate / day during the first three months and thereafter recepies containing 80 g carbohydrate/ day during the remaining 12 months |
| Low Calori diet | Other | Other: Low carb dietParticipants will be asked to by low caloric diet replacement containing 850 kCal/day during the first 3 months, aiming for a weight loss of 10 kg during and thereafter will have access to recepies containing less calorie for weight maintenance during the remaining 12 months |
Who may qualify
- Ages
- 24 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- HbA1c > 48 mmol/mol (with or without medical treatment);
- less than 6 years since the diagnosis of T2D
- BMI ≥ 27 kg/m2 (≥ 25 kg/m2 for Asians).
Key exclusion criteria (7 listed)
- Insulin deficiency.
- HbA1c concentration of 12% or more (≥108 mmol/mol),
- treatment with sulphonyl urea or sodium-glucose-cotrasporter2-inhibitor (SGL2-i),
- myocardial infarction within the previous 6 months,
- severe or unstable heart failure
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Low carb dietAlso: Low calori dietLow calori diet | Other | Low Calori diet, Low Carb diet |
Primary outcome
non-diabetic HbA1c
Time frame: After 3 months
HbA1c below 48 mmol/mol without antidiabetic medication
non diabetic HbA1c
Time frame: After 15 months
HbA1c below 48 mmol/mol without antidiabetic medication
5 secondary outcomes
Changes in HbA1c
Time frame: After 3 and 15 months
Percent of participants with HbA1c below 48 and 42 mmol/mol
Time frame: After 3 and 15 months
Changes in Fasting glucose levels
Time frame: After 3 and 15 months
Changes in HOMA-IR
Time frame: After 3 and 15 months
Changes in Insulin secretion
Time frame: After 3 and 15 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jan 2024.
- Individual participant dataSharing planned: No
Related trials for Diabetes Mellitus Type 2 in Obese
RecruitingPhase 3
A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes
Obesity or Overweight, Type 2 Diabetes
Enrolling by invitationEarly Phase 1
Truway Diagnostic Tools in Primary Care
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight
RecruitingPhase 3
A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes
Obesity, Overweight
RecruitingPhase 3
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
Obesity, Overweight and/or Obesity
RecruitingPhase 3
Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes
Diabetes Mellitus, Type 2
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Neda Rajamand Ekberg, MD, PhD principal investigator
Region Stockholm
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Low carb diet in people with Diabetes Mellitus Type 2 in Obese, run by Region Stockholm at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 2 Jan 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Neda Rajamand Ekberg, M.D. PhD. (+468-123 671 50, neda.ekberg@ki.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
non-diabetic HbA1c (time frame: After 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jan 2024.